Elsevier Inc News Today

More than half of patients recruited for this research showed improvements in wound healing, and a significant number had greater wound stability.

  - In the 2 days immediately after influenza immunization, study participants socially encountered almost twice as many other humans as they did in the 2 days before immunization   CHRIS REIBER, PHD, MPH, ERIC C. SHATTUCK, MS, SEAN FIORE, MS, PAULINE ALPERIN, MS, VANESSA DAVIS, MS, AND JANICE MOORE, PHD PURPOSE: The purpose of…

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric and adult patients Gastroenteropancreatic neuroendocrine...

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17)...

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and...

This report describes the effectiveness of the updated COVID-19 vaccine in preventing hospitalizations in adults with immunocompromising conditions.

Lab automation enhances scientific research efficiency, precision, and safety, while challenges include cost and rapid obsolescence.

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2...

We explore how Raman spectroscopy can be used to analyze and characterize bilayer graphene stacks.

FDA approval of the company’s second US Radioligand Therapy manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyondNew 70,000-square foot RLT facility is the...